BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake in United Therapeutics Co. (NASDAQ:UTHR)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 64.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 32,092 shares of the biotechnology company’s stock after buying an additional 12,566 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.07% of United Therapeutics worth $11,500,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. ClariVest Asset Management LLC raised its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new position in United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics during the third quarter worth about $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of United Therapeutics in the third quarter worth about $82,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $45,293.30. The trade was a 67.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 117,496 shares of company stock valued at $43,765,042. 11.90% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of UTHR opened at $372.89 on Friday. The stock has a market capitalization of $16.65 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. The business’s fifty day moving average price is $365.06 and its 200 day moving average price is $331.82. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.38 EPS. As a group, research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on UTHR shares. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Bank of America dropped their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.